OAKVILLE, ON, June 26 /CNW/ - Nycomed Canada Inc. today announced a
licensing agreement with Chiesi Farmaceutici SpA to market Atimos(R)
(formoterol), a treatment anticipated to be indicated for asthma and Chronic
Obstructive Pulmonary Disease (COPD). In Canada, COPD is the fourth-leading
cause of death among Canadians, and recently The Lung Association reported
that COPD may affect nearly three million diagnosed and undiagnosed Canadians.
